SCHEMBL7073283

SCHEMBL7073283

CCOC(=O)CC1Cc2cc(O)ccc2NC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 1/20 0.47
TSHR P16473 2/20 0.44
HSD17B10 Q99714 2/20 0.44
MIF P14174 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
GAA P10253 3/20 0.38
GLA P06280 2/20 0.38
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C19 P33261 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
NR1I2 O75469 1/20 0.38
GMNN O75496 1/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7076747 0.90 HSD17B1 (0.45) HSD17B1TSHRHSD17B10MIFKMT2A
SCHEMBL7073535 0.89 HSD17B1 (0.40) HSD17B1TSHRHSD17B10MEN1KMT2A
SCHEMBL19055480 0.87 CYP1A2 (0.43) HSD17B1TSHRHSD17B10MEN1KMT2A
SCHEMBL1018625 0.87 TSHR (0.43) HSD17B1TSHRHSD17B10MEN1KMT2A
SCHEMBL8304087 0.84 HSD17B10 (0.55) TSHRHSD17B10MEN1KMT2AGAA
SCHEMBL1016536 0.83 MAPT (0.43) TSHRHSD17B10MEN1KMT2AGAA
SCHEMBL7075428 0.81 BRD4 (0.42) TSHRHSD17B10OPRM1
SCHEMBL7076204 0.80 BRD4 (0.39) HSD17B1TSHRHSD17B10MEN1KMT2A
SCHEMBL5775643 0.80 TSHR (0.46) HSD17B1TSHRHSD17B10MIFMEN1
SCHEMBL5780446 0.78 TSHR (0.44) HSD17B1TSHRHSD17B10MIFMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin WYETH (US) 2003-06-12 US disclosed
US-6429214-B1 INHIBITORS OF BONE RESORPTION WYETH 2002-08-06 US disclosed
EP-1198231-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2002-04-24 EP disclosed
WO-2001007036-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin ITGAV, ITGB2, ITGB3 HSD17B1 2940/4885TSHR 587/4885HSD17B10 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.